AU2010289901A1 - Tumoricidal, bactericidal, or viricidal macrophage activation - Google Patents
Tumoricidal, bactericidal, or viricidal macrophage activation Download PDFInfo
- Publication number
- AU2010289901A1 AU2010289901A1 AU2010289901A AU2010289901A AU2010289901A1 AU 2010289901 A1 AU2010289901 A1 AU 2010289901A1 AU 2010289901 A AU2010289901 A AU 2010289901A AU 2010289901 A AU2010289901 A AU 2010289901A AU 2010289901 A1 AU2010289901 A1 AU 2010289901A1
- Authority
- AU
- Australia
- Prior art keywords
- immobilized
- gcmaf
- mammal
- nagalase
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 61
- 230000004913 activation Effects 0.000 title claims abstract description 19
- 230000002476 tumorcidal effect Effects 0.000 title claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 7
- 230000003253 viricidal effect Effects 0.000 title claims description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 25
- 239000008280 blood Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003446 ligand Substances 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 230000003213 activating effect Effects 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims description 19
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000005348 Neuraminidase Human genes 0.000 claims description 11
- 108010006232 Neuraminidase Proteins 0.000 claims description 11
- 102100038611 Vitamin D-binding protein Human genes 0.000 claims description 10
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 10
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 108010063191 vitamin D-binding protein-macrophage activating factor Proteins 0.000 claims 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 102000019199 alpha-Mannosidase Human genes 0.000 claims 2
- 108010012864 alpha-Mannosidase Proteins 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000012510 hollow fiber Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000012209 synthetic fiber Substances 0.000 claims 2
- 229920002994 synthetic fiber Polymers 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 8
- 244000052613 viral pathogen Species 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010093096 Immobilized Enzymes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002616 plasmapheresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 102000052021 human DBP Human genes 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23608809P | 2009-08-22 | 2009-08-22 | |
| US61/236,088 | 2009-08-22 | ||
| PCT/US2010/046356 WO2011028485A2 (en) | 2009-08-22 | 2010-08-23 | Tumoricidal, bactericidal, or viricidal macrophage activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010289901A1 true AU2010289901A1 (en) | 2012-03-15 |
Family
ID=43649882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010289901A Abandoned AU2010289901A1 (en) | 2009-08-22 | 2010-08-23 | Tumoricidal, bactericidal, or viricidal macrophage activation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110123591A1 (enExample) |
| EP (1) | EP2467154A4 (enExample) |
| CN (1) | CN102596223A (enExample) |
| AU (1) | AU2010289901A1 (enExample) |
| CA (1) | CA2771900A1 (enExample) |
| IN (1) | IN2012DN02200A (enExample) |
| TW (1) | TW201113372A (enExample) |
| WO (1) | WO2011028485A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694088B1 (en) * | 2011-04-07 | 2017-06-07 | Efranat Ltd. | Macrophage activating factor for pharmaceutical compositions |
| EP3563864A1 (en) * | 2013-01-18 | 2019-11-06 | Kline, Ellis | Selective glycosidase regimen for immune programming and treatment of cancer |
| CN111601606A (zh) * | 2017-11-29 | 2020-08-28 | 菲格内有限责任公司 | 用于活化的成纤维细胞与免疫细胞的相互作用及其用途 |
| US12485174B2 (en) | 2019-06-27 | 2025-12-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | HDAC6-activated macrophages, compositions, and uses thereof |
| RU2717218C1 (ru) * | 2019-08-07 | 2020-03-18 | Зайцева Инга Николаевна | Способ торможения роста подкожного трансплантата экспериментальной глиобластомы человека u-87, перевитого иммунодефицитным мышам nu/j |
| CN114854579A (zh) * | 2022-04-13 | 2022-08-05 | 武汉大学 | 可用于临床的外周血特定亚群细胞外囊泡分离平台 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410269B1 (en) * | 1995-06-07 | 2002-06-25 | Nobuto Yamamoto | Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| US20050103712A1 (en) * | 2003-11-13 | 2005-05-19 | Voyce Brian D. | Methods and devices for treating severe peripheral bacterial infections |
-
2010
- 2010-08-23 IN IN2200DEN2012 patent/IN2012DN02200A/en unknown
- 2010-08-23 US US12/861,575 patent/US20110123591A1/en not_active Abandoned
- 2010-08-23 WO PCT/US2010/046356 patent/WO2011028485A2/en not_active Ceased
- 2010-08-23 CA CA2771900A patent/CA2771900A1/en not_active Abandoned
- 2010-08-23 AU AU2010289901A patent/AU2010289901A1/en not_active Abandoned
- 2010-08-23 TW TW099128181A patent/TW201113372A/zh unknown
- 2010-08-23 CN CN2010800374048A patent/CN102596223A/zh active Pending
- 2010-08-23 EP EP10814210A patent/EP2467154A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW201113372A (en) | 2011-04-16 |
| EP2467154A2 (en) | 2012-06-27 |
| CN102596223A (zh) | 2012-07-18 |
| EP2467154A4 (en) | 2013-03-27 |
| WO2011028485A3 (en) | 2011-07-14 |
| CA2771900A1 (en) | 2011-03-10 |
| US20110123591A1 (en) | 2011-05-26 |
| WO2011028485A2 (en) | 2011-03-10 |
| IN2012DN02200A (enExample) | 2015-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
| US20230085710A1 (en) | Novel polyinosinic - polycytidylic acid compositions | |
| US20110123591A1 (en) | Tumoricidal, bactericidal, or viricidal macrophage activation | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| Prutchi‐Sagiv et al. | Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? | |
| CN104955941A (zh) | 免疫抑制细胞及其制造和使用方法 | |
| Gardam et al. | Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma | |
| Tao et al. | New insights into immune cells and immunotherapy for thyroid cancer | |
| JP2022541293A (ja) | がん細胞療法用のｐ２１発現単球 | |
| EP4435101A1 (en) | Membrane surface protein containing gpi anchor region | |
| US20160206699A1 (en) | Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies | |
| US20160008435A1 (en) | Composition for preventing or treating b-cell lymphoma comprising il-21 expressing mesenchymal stem cells | |
| RU2593003C2 (ru) | Препарат экзосом - онкосом и способ иммунотерапии солидных опухолей с его использованием | |
| WO2011088402A2 (en) | The use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients | |
| Bogacz et al. | Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors | |
| Zhang et al. | Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles | |
| CN109793889B (zh) | 一种肿瘤疫苗及其制备方法 | |
| CN114762730A (zh) | Pcsk9在肿瘤免疫治疗、增强免疫细胞免疫效应中的应用 | |
| CN119745853B (zh) | 小分子化合物c2在制备治疗恶性肿瘤的制剂或药物中的应用 | |
| García-Martínez et al. | Adverse prognosis of GM-CSF expression in human cutaneous melanoma | |
| Kong et al. | Clonally expanded, targetable, natural killer-like NKG7 T cells seed the aged spinal cord | |
| Lunavat et al. | Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity | |
| CN120590545A (zh) | 包括cd40l和il7的融合蛋白及其在制备治疗肿瘤药物中的应用 | |
| CN117143250A (zh) | 一种IL-15/IL-15Rα融合基因、载体、工程化脂肪细胞及其制备方法 | |
| KR20250162896A (ko) | 종양 치료 전계 및 킬러 세포를 사용한 암 치료를 위한 조성물, 시스템, 및 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |